Cellebrite DI (NASDAQ:CLBT) Upgraded to "Buy" at Wall Street Zen

Key Points

• Cellebrite DI (NASDAQ:CLBT) was upgraded from a "hold" to a "buy" rating by Wall Street Zen, indicating positive investor sentiment towards the company's stock.
• Despite Needham & Company and JPMorgan reducing their price targets, the stock still holds an average rating of "Buy" with a consensus price target of $21.00.
• The company's recent earnings report showed a positive performance, with $0.12 earnings per share, exceeding the expected $0.11, and an 18.4% year-over-year revenue increase to $113.28 million.

Wall Street Zen upgraded shares of Cellebrite DI (NASDAQ:CLBT - Free Report) from a hold rating to a buy rating in a research report sent to investors on Saturday morning.

Other research analysts have also recently issued reports about the stock. Lake Street Capital lowered their target price on shares of Cellebrite DI from $24.00 to $22.00 and set a "buy" rating on the stock in a report on Friday, August 15th. JPMorgan Chase & Co. lowered their target price on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, May 12th. Finally, Needham & Company LLC lowered their target price on shares of Cellebrite DI from $24.00 to $18.00 and set a "buy" rating on the stock in a report on Thursday, August 14th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $22.40.

Cellebrite DI Stock Down 2.0%

Shares of CLBT traded down $0.32 during mid-day trading on Friday, hitting $15.48. 1,678,504 shares of the company's stock were exchanged, compared to its average volume of 2,345,980. Cellebrite DI has a 52 week low of $13.10 and a 52 week high of $26.30. The stock's 50-day simple moving average is $14.95 and its 200-day simple moving average is $17.65. The firm has a market cap of $3.71 billion, a price-to-earnings ratio of -20.37, a price-to-earnings-growth ratio of 3.13 and a beta of 1.27.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last announced its earnings results on Thursday, August 14th. The company reported $0.12 EPS for the quarter, topping the consensus estimate of $0.11 by $0.01. Cellebrite DI had a negative net margin of 34.56% and a positive return on equity of 23.92%. The company had revenue of $113.28 million for the quarter, compared to analysts' expectations of $112.33 million. During the same period last year, the firm earned $0.10 earnings per share. The business's revenue for the quarter was up 18.4% on a year-over-year basis. Cellebrite DI has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. Analysts forecast that Cellebrite DI will post 0.3 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in CLBT. Ashford Capital Management Inc. grew its stake in shares of Cellebrite DI by 2.2% during the second quarter. Ashford Capital Management Inc. now owns 1,265,670 shares of the company's stock worth $20,251,000 after buying an additional 27,830 shares during the last quarter. SkyView Investment Advisors LLC grew its stake in shares of Cellebrite DI by 2.6% during the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company's stock worth $597,000 after buying an additional 970 shares during the last quarter. Tidal Investments LLC grew its stake in shares of Cellebrite DI by 60.9% during the second quarter. Tidal Investments LLC now owns 96,157 shares of the company's stock worth $1,539,000 after buying an additional 36,402 shares during the last quarter. Select Equity Group L.P. bought a new stake in shares of Cellebrite DI during the second quarter worth $5,558,000. Finally, Man Group plc grew its stake in shares of Cellebrite DI by 44.1% during the second quarter. Man Group plc now owns 731,589 shares of the company's stock worth $11,705,000 after buying an additional 223,941 shares during the last quarter. 45.88% of the stock is owned by institutional investors.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.